Safety Evaluation of Tradipitant Dosing in 4-Organ Human-on-a-Chip System to be Presented at SOT 2026
A 4-organHuman-on-a-Chip® model was used to study the safety profile of tradipitant, the results supported its recent approval for motion sickness.
Presentation Details
Safety Evaluation of Supraphysiological Tradipitant Dosing under Differential Liver Metabolism
Presented by: Jessie Carlin, Ph.D., Vanda Pharmaceuticals
Monday, March 23, 2026, 4:15 PM PDT
Ballroom 6C
Learn more and discover how we can advance your pipeline faster and more efficiently
Explore Other Hesperos News
Human-on-a-Chip Safety Data for Tradipitant to be Presented at SOT 2026
A 4-organHuman-on-a-Chip® model was used to study the safety profile of tradipitant, the results supported its recent approval for motion sickness.
Advanced Science Cover Page Features Hesperos’ Malaria-on-a-Chip Model
Featured on the cover of Advanced Science, our study presents a human-derived Malaria-on-a-Chip system that captures the biology of infection and delivers actionable insights for real-world therapeutic translation.
Announcing Strategic Channel Sales Partnership with AsedaSciences for Better Predictive, More Efficient, & Lower Cost Drug/Product Development
Hesperos and AsedaSciences announce a strategic channel sales partnership combining Human-on-a-Chip® and AI-driven 3RnD® to advance safer, more efficient drug and chemical development.